Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Qarziba (dinutuximab beta)
i
Other names:
APN 311, ch14.18/CHO
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(2)
News
Trials
Company:
Apeiron Biologics, BeiGene, Jazz, Recordati
Drug class:
GD2 ganglioside inhibitor
Related drugs:
‹
naxitamab-gqgk (1)
dinutuximab (1)
BCD-245 (0)
TRBS07 (0)
GD2-GD3 Vaccine (0)
GD2-SADA (0)
KUR-501 (0)
Hu14.18K322A (0)
APN301 (0)
GD2xCD3 (0)
naxitamab-gqgk (1)
dinutuximab (1)
BCD-245 (0)
TRBS07 (0)
GD2-GD3 Vaccine (0)
GD2-SADA (0)
KUR-501 (0)
Hu14.18K322A (0)
APN301 (0)
GD2xCD3 (0)
›
Associations
(2)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Neuroblastoma
No biomarker
Neuroblastoma
dinutuximab beta
Sensitive: A1 - Approval
dinutuximab beta
Sensitive
:
A1
dinutuximab beta
Sensitive: A1 - Approval
dinutuximab beta
Sensitive
:
A1
B4GALNT1 expression
Ewing Sarcoma
B4GALNT1 expression
Ewing Sarcoma
dinutuximab beta
Sensitive: C3 – Early Trials
dinutuximab beta
Sensitive
:
C3
dinutuximab beta
Sensitive: C3 – Early Trials
dinutuximab beta
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login